News LigaChem Biosciences Inc.

Equities

A141080

KR7141080002

End-of-day quote Korea S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
65,700 ^KRW	-1.20%		-3.95%	+1.08%

08/04	NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	CI
29/03	Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	08/04	CI
Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.	29/03	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing	09/02	MT
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing	08/02	AQ
Orion Set to Acquire 25% Stake in LegoChem Biosciences	17/01	MT
South Korean Shares Close Lower Amid Geopolitical Tension	16/01	MT
Legochem Biosciences to Raise 469.8 Billion Won through Rights Issue; Shares Fall 5%	16/01	MT
LegoChem Biosciences, Inc. announced that it expects to receive KRW 1018.327793998 billion in funding from Pan Orion Corp. Ltd.	15/01	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	28/12	CI
LegoChem Biosciences, Inc.'s Equity Buyback announced on June 28, 2023, has expired with 140,000 shares, representing 0.53% for KRW 4,879.08 million.	28/12	CI
J&J: licensing agreement with Korea's LegoChem in ADCs	27/12	CF
Legochem Biosciences Announces License Agreement for Lcb84 Trop2-Targeted ADC	26/12	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
LegoChem Biosciences Selects BostonGene as Genomic Partner for First-in-Human Clinical Trial	08/11	AQ
BostonGene and LegoChem Biosciences, Inc. Announce Collaboration to Support Phase I/II Study of LCB84, TROP2-Directed ADC, in Patients with Advanced Cancers	07/11	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	04/23/04	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	04/23/04	CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 5.9999904 billion in funding from LegoChem Biosciences, Inc.	05/23/05	CI
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 5.9999904 billion in funding from LegoChem Biosciences, Inc.	28/23/28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News LigaChem Biosciences Inc.

Equities

A141080

KR7141080002

Summary

Filters